Cytodyn Inc
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colo… Read more
Cytodyn Inc (CYDY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of November 2025: 0.036x
Based on the latest financial reports, Cytodyn Inc (CYDY) has a cash flow conversion efficiency ratio of 0.036x as of November 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.35 Million) by net assets ($-119.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cytodyn Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Cytodyn Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cytodyn Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytodyn Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yindu Kitchen Equipment Co Ltd
SHG:603277
|
0.076x |
|
Citizens Financial Services Inc. Common Stock
NASDAQ:CZFS
|
0.049x |
|
Gorilla Technology Group Inc.
NASDAQ:GRRR
|
-0.013x |
|
Samhyun
KQ:437730
|
0.029x |
|
AnHui Annada Titanium Industry Co Ltd
SHE:002136
|
-0.008x |
|
Dezhou United Petroleum Technology Co.Ltd.
SHE:301158
|
0.014x |
|
Beijing Bohui Innovation Technology Co Ltd
SHE:300318
|
-0.027x |
|
ShenZhen Zero-Seven Co Ltd
SHE:000007
|
0.554x |
Annual Cash Flow Conversion Efficiency for Cytodyn Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Cytodyn Inc from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-05-31 | $-96.04 Million | $-8.77 Million | 0.091x | -2.97% |
| 2024-05-31 | $-116.76 Million | $-10.98 Million | 0.094x | -58.98% |
| 2023-05-31 | $-109.50 Million | $-25.11 Million | 0.229x | -72.15% |
| 2022-05-31 | $-94.40 Million | $-77.72 Million | 0.823x | -85.28% |
| 2021-05-31 | $-21.02 Million | $-117.57 Million | 5.594x | -79.83% |
| 2020-05-31 | $-2.48 Million | $-68.80 Million | 27.738x | +389.95% |
| 2019-05-31 | $-8.91 Million | $-50.47 Million | 5.661x | +149.16% |
| 2018-05-31 | $-13.16 Million | $-29.90 Million | 2.272x | -90.62% |
| 2017-05-31 | $-1.10 Million | $-26.73 Million | 24.231x | +1096.70% |
| 2016-05-31 | $10.21 Million | $-24.81 Million | -2.431x | -316.32% |
| 2015-05-31 | $-10.69 Million | $-12.02 Million | 1.124x | +159.67% |
| 2014-05-31 | $3.92 Million | $-7.39 Million | -1.883x | -112.43% |
| 2013-05-31 | $-223.92K | $-3.39 Million | 15.153x | -- |